Б.Ариунзаяа
Loading...
Товч нэр
Б.Ариунзаяа
Бүтэн нэр
Бат-Эрдэнэ Ариунзаяа
Латин нэр
Bat-Erdene Ariunzaya
Албан тушаал
Ахлах багш
Харьяалал
ORCID
Scopus Author ID
4 results
Now showing 1 - 4 of 4
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma(2021-04) ;Watanabe, Keiichiro; ;Tenshin, Hirofumi ;Cui, QuTeramachi, JumpeiScopus© Citations 7 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat(2020-04) ;Ashtar, Mohannad ;Tenshin, Hirofumi ;Teramachi, Jumpei; Hiasa, MasahiroReceptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically used for prevention of tumor lysis syndrome, has been demonstrated to effectively inhibit not only the generation of uric acid but also the formation of reactive oxygen species (ROS). ROS has been demonstrated to mediate RANKL-mediated osteoclastogenesis. In the present study, we therefore explored the role of cancer-treatment-induced ROS in RANKL-mediated osteoclastogenesis and the suppressive effects of febuxostat on ROS generation and osteoclastogenesis. RANKL dose-dependently induced ROS production in RAW264.7 preosteoclastic cells; however, febuxostat inhibited the RANKL-induced ROS production and osteoclast (OC) formation. Interestingly, doxorubicin (Dox) further enhanced RANKL-induced osteoclastogenesis through upregulation of ROS production, which was mostly abolished by addition of febuxostat. Febuxostat also inhibited osteoclastogenesis enhanced in cocultures of bone marrow cells with MM cells. Importantly, febuxostat rather suppressed MM cell viability and did not compromise Dox's anti-MM activity. In addition, febuxostat was able to alleviate pathological osteoclastic activity and bone loss in ovariectomized mice. Collectively, these results suggest that excessive ROS production by aberrant RANKL overexpression and/or anticancer treatment disadvantageously impacts bone, and that febuxostat can prevent the ROS-mediated osteoclastic bone damage.Scopus© Citations 43 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Myeloma cell growth suppression by osteoblast-derived extracellular vesicles: the creation of a non-permissive niche for myeloma cells by bone-forming osteoblasts(2025-06) ;Kim, SooHa ;Teramachi, Jumpei ;Hiasa, Masahiro ;Amachi, RyotaScopus© Citations 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Mutual amplification of sensory nerve outgrowth and tumor progression in myeloma(2026-08) ;Nakagawa, Motosumi ;Hiasa, Masahiro ;Teramachi, Jumpei ;Harada, TakeshiOda, Asuka
